These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 11466700)
1. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Bahar AY; Taylor PJ; Andrews L; Proos A; Burnett L; Tucker K; Friedlander M; Buckley MF Cancer; 2001 Jul; 92(2):440-5. PubMed ID: 11466700 [TBL] [Abstract][Full Text] [Related]
2. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153 [TBL] [Abstract][Full Text] [Related]
3. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Roa BB; Boyd AA; Volcik K; Richards CS Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191 [TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756 [TBL] [Abstract][Full Text] [Related]
5. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909 [TBL] [Abstract][Full Text] [Related]
6. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978 [TBL] [Abstract][Full Text] [Related]
7. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781 [TBL] [Abstract][Full Text] [Related]
10. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298 [TBL] [Abstract][Full Text] [Related]
11. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192 [TBL] [Abstract][Full Text] [Related]
12. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
13. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Fodor FH; Weston A; Bleiweiss IJ; McCurdy LD; Walsh MM; Tartter PI; Brower ST; Eng CM Am J Hum Genet; 1998 Jul; 63(1):45-51. PubMed ID: 9634504 [TBL] [Abstract][Full Text] [Related]
14. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077 [TBL] [Abstract][Full Text] [Related]
15. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Díez O; Osorio A; Robledo M; Barroso A; Domènech M; Cortés J; Albertos J; Sanz J; Brunet J; SanRomán JM; Alonso MC; Baiget M; Benítez J Br J Cancer; 1999 Mar; 79(7-8):1302-3. PubMed ID: 10098775 [TBL] [Abstract][Full Text] [Related]
17. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews. Lalloo F; Cochrane S; Bulman B; Varley J; Elles R; Howell A; Evans DG J Med Genet; 1998 Jan; 35(1):10-2. PubMed ID: 9475087 [TBL] [Abstract][Full Text] [Related]
18. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794 [TBL] [Abstract][Full Text] [Related]
19. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676 [TBL] [Abstract][Full Text] [Related]
20. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]